<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00839631</url>
  </required_header>
  <id_info>
    <org_study_id>T08-1</org_study_id>
    <nct_id>NCT00839631</nct_id>
  </id_info>
  <brief_title>Dose Escalation Study of EC D-3263 HCl in Advanced Solid Tumors</brief_title>
  <official_title>A Phase 1, Open Label, Dose Escalation Study Evaluating the Safety and Pharmacokinetics of Enteric Coated D-3263 Hydrochloride in Subjects With Advanced Solid Tumors</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Dendreon</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Dendreon</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a Phase 1, dose escalation study evaluating safety and pharmacokinetics of enteric
      coated D-3263 HCl in subjects with advanced solid tumors
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>March 2009</start_date>
  <completion_date type="Actual">April 2012</completion_date>
  <primary_completion_date type="Actual">December 2011</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Assess the safety of EC D-3263 HCl</measure>
    <time_frame>weekly</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Determine the maximum tolerated dose of EC D-3263 HCl administered orally daily</measure>
    <time_frame>weekly</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Characterize the pharmacokinetic profile of EC D-3263 HCl after a single dose and repeat daily dosing</measure>
    <time_frame>periodically within the first month, weekly thereafter</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>preliminary assessment of antitumor activity</measure>
    <time_frame>1 month, periodically thereafter</time_frame>
  </secondary_outcome>
  <enrollment type="Actual">23</enrollment>
  <condition>Solid Tumors</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>EC D-3263 HCl</intervention_name>
    <description>EC D-3263 HCl, capsules, 50 mg. Oral administration. Dose escalation cohorts (cycle one: single dose on Day 1, daily doses on day 8-28; subsequent cycles: 1 week drug holiday followed by 3 weeks of daily dosing). Expansion Cohort: daily dosing for 28 days followed by a single 7 day drug holiday (Cycle 1), continuing thereafter with daily dosing.</description>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  histologically or cytologically confirmed advanced solid tumor malignancy which is
             either refractory to standard therapy or for which no standard therapy exists

          -  measurable or evaluable disease

          -  &gt;= 18 years of age

          -  ECOG of 0, 1 or 2

          -  no treatement with chemotherapy, radiotherapy or other systemic therapy (excluding
             depot LHRH agonist or antagonist for subjects with prostate cancer) for the treatment
             of his or her tumor with in 28 days prior to receipt of EC D-3263 HCl

        Exclusion Criteria:

          -  Clinically significant coronary artery disease or conduction system abnormality

          -  Coagulation disorder

          -  Active infection requiring the use of systemic antimicrobial medications within seven
             days prior to receipt of EC D-3263 HCl

          -  Any major surgery within 28 days prior to receipt of EC D-3263 HCl
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>South Texas Accelerated Research Therapeutics (START)</name>
      <address>
        <city>San Antonio</city>
        <state>Texas</state>
        <zip>78229</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>April 2012</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>February 6, 2009</study_first_submitted>
  <study_first_submitted_qc>February 6, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 9, 2009</study_first_posted>
  <last_update_submitted>April 30, 2012</last_update_submitted>
  <last_update_submitted_qc>April 30, 2012</last_update_submitted_qc>
  <last_update_posted type="Estimate">May 2, 2012</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>subjects with advanced solid tumors refractory to standard therapy or for whom no effective therapy is available.</keyword>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

